Ultragenyx Pharmaceutical Inc. (RARE) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Ultragenyx Pharmaceutical Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -3.94x | -6.69x | -5.80x | -4.58x | -12.56x | -45.15x |
| P/B Ratio | -28.35x | 14.92x | 12.77x | 9.19x | 6.18x | 7.30x |
| P/S Ratio | 3.37x | 6.80x | 8.10x | 8.92x | 16.22x | 31.08x |
| Profitability | ||||||
| Gross Margin | 83.8% | 86.3% | 89.6% | 92.2% | 95.4% | 97.7% |
| Operating Margin | -79.5% | -95.7% | -131.1% | -178.6% | -108.6% | -121.8% |
| Net Margin | -85.4% | -101.6% | -139.7% | -194.7% | -129.2% | -68.8% |
| EBITDA Margin | -74.3% | -83.7% | -118.9% | -176.3% | -116.8% | -51.6% |
| Liquidity | ||||||
| Current Ratio | 2.48x | 2.37x | 2.61x | 3.38x | 4.72x | 6.83x |
| Quick Ratio | 2.34x | 2.24x | 2.49x | 3.28x | 4.63x | 6.76x |
| Leverage | ||||||
| Debt/Equity | -15.95x | 0.16x | 0.16x | 0.09x | 0.05x | 0.04x |
YoY = year-over-year change. Source: FMP..